Where Cross-Border Deal Flow Actually Happens 

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Every VC and PE firm says they want cross-border deal flow. Few have it. Most cross-border relationships stop at an introduction that never becomes a term sheet, because access without real syndicate standing on the other side rarely converts.

At RESI Boston 2026, Life Science Nation is convening a Cross-Border Investor Luncheon with Simon Hua, Chairman of BioMetas, to explore how cross-border access actually works through one of the hardest markets to enter.

Simon spent fifteen years in investment banking in Hong Kong, then a decade building and scaling the equity-for-service model that turns CRO relationships into equity stakes and syndicate seats, first at Viva Biotech, then ChemPartner, and now BioMetas. He has led CROs and his own fund, CFS Capital, to incubate and invest in over 100 innovative biotechs globally, while building an ecosystem with academic research institutions, government platforms, and VCs including Huagai Capital, E-Fund Capital, and Qiming Venture Partners.

The luncheon is built around a simple premise: bring together VCs and PE firms that want genuine syndicate relationships outside their own region, with funds that can send them deal flow and receive it in return.

Simon will speak directly to how that access works: how the equity-for-service model surfaces promising biotechs before they are broadly shopped, and how that early visibility converts into syndicate seats alongside the region’s leading investors.

Whether you are looking east or west, the practical question is the same:

How do you actually get inside?

*You must be an active VC investment firm that makes direct investments into life science and healthcare companies for us to approve your RSVP.